Compare PGEN & AERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | AERO |
|---|---|---|
| Founded | 1998 | 1934 |
| Country | United States | Mexico |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2013 | 2023 |
| Metric | PGEN | AERO |
|---|---|---|
| Price | $6.86 | $14.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $8.33 | ★ $28.57 |
| AVG Volume (30 Days) | ★ 6.2M | 295.1K |
| Earning Date | 05-13-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $1,115.92 | $11.85 |
| Revenue Next Year | $81.04 | $4.57 |
| P/E Ratio | $231.00 | ★ $7.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.99 | $12.26 |
| 52 Week High | $7.72 | $23.05 |
| Indicator | PGEN | AERO |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 42.99 |
| Support Level | $3.96 | $13.15 |
| Resistance Level | $7.32 | $16.84 |
| Average True Range (ATR) | 0.39 | 0.68 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 51.38 | 43.85 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.